All In Biotech

Free tool

FAERS Monitor: Naphcon-A

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020226 or its brand name (Naphcon-A, Naphazoline Hydrochloride, Pheniramine Maleate). Reports on generic versions are filed under their own applications.

Reports

295

Serious

28

9% of reports

Hospitalization

5

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective126
  • eye irritation55
  • eye pain27
  • ocular hyperaemia22
  • mydriasis20
  • vision blurred19
  • dry eye12
  • headache11
  • dizziness10
  • eye pruritus10
  • fatigue9
  • nausea9
  • product quality issue9
  • expired product administered7
  • pain7

Reports by year received

View as table
YearReports
20132
20145
201510
201631
201752
201888
20199
202017
202129
202212
20238
202410
202513
20269

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,864 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mydriasisSignal20111.372.92,075
eye irritationSignal5568.253.73,581
eye painSignal2734.123.8837
ocular hyperaemiaSignal2233.122.1654
eye pruritusSignal1021.211.5173
dry eyeSignal1217.19.8167
expired product administeredSignal715.07.278
vision blurredSignal199.96.4144
drug ineffectiveSignal1266.86.0661
product quality issueSignal94.72.523
dizziness101.40.81
headache111.30.70
fatigue90.80.40
pain70.80.40
nausea90.80.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.